See also Antineoplastic Agents. Action/Kinetics: Acts as a mitotic inhibitor at the G2 portion of the cell cycle to inhibit DNA synthesis. At high doses, cells entering mitosis are lysed, whereas at low doses, cells will not enter prophase. tv2: biphas-ic, initial, 1.5 hr; final, 4-11 hr. Effective plasma levels: 0.3-10 mcg/mL. Poor CNS penetration. Eliminated through both the urine and bile unchanged and as liver metabolites. Is water soluble.
Uses: With combination therapy to treat refractory testicular tumors and small cell lung cancer. Non-FDA Approved Uses: Alone or in combination to treat acute monocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, AIDS-associated Kaposi's sarcoma, Ewing's sarcoma. Also, choriocarcinoma; hepatocellular carcinoma; nonsmall cell lung, breast, endometrial, and gastric cancers; acute lymphocytic leukemia; soft tissue carcinoma; rhabdomyo-sarcoma.
Contraindications: Lactation. Special Concerns: Safety and efficacy in children have not been established. Severe myelosuppression may occur.
Additional Side Effects: Anaphylac-tic-type reactions, hypotension, peripheral neuropathy, somnolence.
How Supplied: Capsule: 50 mg; Injection: 20 mg/mL; Powder for injection: 100 mg
Was this article helpful?
This guide will help millions of people understand this condition so that they can take control of their lives and make informed decisions. The ebook covers information on a vast number of different types of neuropathy. In addition, it will be a useful resource for their families, caregivers, and health care providers.